Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 3:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 94 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: placebo vehicle gel Clear all
Completed Phase 3 Interventional

Efficacy and Safety of Diclofenac Sodium Gel (DSG) in Knee Osteoarthritis

NCT00426621
View directory record Official record
Conditions
Osteoarthritis of the Knee
Interventions
Diclofenac Sodium Gel, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
35 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
64
States / cities
Mobile, Alabama • Tallassee, Alabama • Chandler, Arizona + 59 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2007 · Synced Oct 8, 2026, 3:26 AM EDT
Completed Phase 3 Interventional Results available

A Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris

NCT03028363
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Olumacostat Glasaretil Gel, 5.0%, Olumacostat Glasaretil Gel, Vehicle
Drug · Other
Lead sponsor
Dermira, Inc.
Industry
Eligibility
9 Years and older
Enrollment
759 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
38
States / cities
Phoenix, Arizona • Anaheim, California • Los Angeles, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2021 · Synced Oct 8, 2026, 3:26 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Phase 2, Safety & Microbiology Study of C16G2 in Multiple Oral Gel &/or Mouth Rinse Doses to Healthy Adults

NCT02044081
View directory record Official record
Conditions
Dental Caries
Interventions
C16G2 Rinse, Placebo, C16G2 Gel
Drug
Lead sponsor
Armata Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
2
States / cities
Kalispell, Montana • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 1, 2019 · Synced Oct 8, 2026, 3:26 AM EDT
Not listed Phase 2 Interventional

Efficacy Study of Tempol to Prevent Hair Loss From Radiotherapy to the Brain

NCT00801086
View directory record Official record
Conditions
Alopecia
Interventions
7% (w/v) Tempol alcohol-based gel (MTS-01), alcohol-based gel
Drug
Lead sponsor
Mitos Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
2
States / cities
Tucson, Arizona • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 3, 2008 · Synced Oct 8, 2026, 3:26 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome

NCT06050122
View directory record Official record
Conditions
Gorlin Syndrome
Interventions
Patidegib Topical Gel, Patidegib Topical Gel with no active patidegib
Drug
Lead sponsor
Sol-Gel Technologies, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
24
States / cities
Rogers, Arkansas • Fremont, California • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 8, 2026, 3:26 AM EDT
Completed Phase 4 Interventional Results available

A Five Day Clinical Study to Examine the Effects of a Benzoyl Peroxide Treatment on Facial Acne Lesions

NCT02052752
View directory record Official record
Conditions
Skin Diseases
Interventions
3% Benzoyl Peroxide, 3% Benzoyl Peroxide Placebo, Neutrogena Rapid Clear®
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years to 45 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated May 18, 2015 · Synced Oct 8, 2026, 3:26 AM EDT
Completed Phase 3 Interventional Results available

A Multi-center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on the Head (Face or Scalp)

NCT00916006
View directory record Official record
Conditions
Actinic Keratosis
Interventions
PEP005 Gel, Vehicle gel
Drug
Lead sponsor
Peplin
Industry
Eligibility
18 Years and older
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
19
States / cities
Los Angeles, California • Oceanside, California • San Diego, California + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2015 · Synced Oct 8, 2026, 3:26 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Safety and the Efficacy of EscharEx (EX-02 Formulation) in Debridement of Venous Leg Ulcers

NCT03588130
View directory record Official record
Conditions
Venous Leg Ulcer
Interventions
EscharEx (5% EX-02 formulation), Gel Vehicle, Non-surgical standard of care (NSSOC)
Drug
Lead sponsor
MediWound Ltd
Industry
Eligibility
18 Years to 90 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
21
States / cities
Carlsbad, California • Fresno, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2022 · Synced Oct 8, 2026, 3:26 AM EDT
Completed Phase 3 Interventional Results available

Comparison Between Podofilox Topical Gel 0.5% and Allergan's Condylox® Gel 0.5% for External Anogenital Warts

NCT03532776
View directory record Official record
Conditions
External Anogenital Warts
Interventions
Podofilox Gel 0.5%, Condylox Topical Gel 0.5%, Placebo Gel
Drug
Lead sponsor
Dermax SA
Industry
Eligibility
18 Years to 65 Years
Enrollment
466 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
4
States / cities
Miami, Florida • Philadelphia, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 27, 2021 · Synced Oct 8, 2026, 3:26 AM EDT
Terminated Phase 3 Interventional

Phase 3 Study Evaluating Efficacy and Safety of DSC127 Compared With Vehicle and With Standard-of-care in Diabetic Foot Ulcers

NCT01849965
View directory record Official record
Conditions
Diabetic Foot Ulcers
Interventions
DSC127, placebo vehicle gel, Standard of Care gel, Aquasite
Drug
Lead sponsor
Integra LifeSciences Corporation
Industry
Eligibility
18 Years and older
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
33
States / cities
Mesa, Arizona • Phoenix, Arizona • Castro Valley, California + 25 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Oct 8, 2026, 3:26 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Phase II Study of AP0302 5% Versus a Vehicle Comparator

NCT02324985
View directory record Official record
Conditions
Pain, Delayed Onset Muscle Soreness
Interventions
S-Ibuprofen Topical Gel 5%, Vehicle Topical Gel
Drug
Lead sponsor
Aponia Laboratories, Inc.
Industry
Eligibility
18 Years to 35 Years
Enrollment
147 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Feb 25, 2019 · Synced Oct 8, 2026, 3:26 AM EDT
Completed Phase 2 Interventional Results available

Topical NVN1000 for the Treatment of External Genital and Perianal Warts

NCT02462187
View directory record Official record
Conditions
Genital Warts, Perianal Warts
Interventions
NVN1000 8% Gel, NVN1000 16%, Vehicle, NVN1000 24%
Drug
Lead sponsor
Novan, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
15
States / cities
Fountain Valley, California • Lomita, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2023 · Synced Oct 8, 2026, 3:26 AM EDT
Completed Phase 4 Interventional

Comparison of Tazarotene and Minocycline Therapies for Maintenance of Facial Acne Vulgaris

NCT00145106
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Tazarotene 0.1% gel + placebo capsule, Oral minocycline (100 mg capsule) + vehicle gel, Tazarotene 0.1% gel + oral minocycline (100 mg capsule)
Drug
Lead sponsor
KGL, Inc.
Other
Eligibility
12 Years and older
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002
U.S. locations
1
States / cities
Broomall, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 15, 2005 · Synced Oct 8, 2026, 3:26 AM EDT
Not listed Phase 2Phase 3 Interventional

Safety and Efficacy of Pro-ocular™ 1% in Daily Scleral Lens Wearing Patients With Ocular Graft-versus-Host Disease

NCT04769648
View directory record Official record
Conditions
Ocular Graft-versus-host Disease
Interventions
Pro-ocular™ Topical Gel 1%, Placebo
Drug
Lead sponsor
Glia, LLC
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Needham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 24, 2023 · Synced Oct 8, 2026, 3:26 AM EDT
Completed Phase 3 Interventional Results available

Periocline as an Adjunct to Scaling and Root Planing for Adult Periodontitis

NCT00529555
View directory record Official record
Conditions
Adult Periodontitis
Interventions
minocycline HCl 2.1%, Scaling and root planing
Drug · Procedure
Lead sponsor
Sunstar Americas
Industry
Eligibility
18 Years and older
Enrollment
602 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
10
States / cities
Birmingham, Alabama • San Francisco, California • Gainsville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated May 9, 2014 · Synced Oct 8, 2026, 3:26 AM EDT
Completed Phase 2 Interventional Results available

A Study of DER 45-EV Gel to Treat Rosacea

NCT00940992
View directory record Official record
Conditions
Rosacea
Interventions
DER 45 EV, Vehicle
Drug
Lead sponsor
Sol-Gel Technologies, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
10
States / cities
Miami, Florida • Augusta, Georgia • Fridley, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2015 · Synced Oct 8, 2026, 3:26 AM EDT
Completed Phase 3 Interventional Results available

An Equivalence Study of Generic Ingenol Mebutate Gel 0.015% and Picato Gel 0.015% in Subjects With Actinic Keratosis

NCT03200912
View directory record Official record
Conditions
ACTINIC KERATOSIS
Interventions
Ingenol Mebutate (Picato®), Generic Ingenol Mebutate, Vehicle Foam
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years to 95 Years
Enrollment
507 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
23
States / cities
Oceanside, California • Denver, Colorado • Aventura, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2020 · Synced Oct 8, 2026, 3:26 AM EDT
Completed Phase 1Phase 2 Interventional

Safety, Pharmacokinetics and Efficacy of FMX114 Versus Vehicle in Adults With Atopic Dermatitis

NCT04927572
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
FMX114, Vehicle
Drug · Other
Lead sponsor
Vyne Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
4
States / cities
Miami, Florida • Miramar, Florida • Sugarloaf, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 31, 2022 · Synced Oct 8, 2026, 3:26 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study to Treat Bacterial Vaginosis

NCT01621399
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
Product 55394, Placebo Vehicle (non-treatment)
Drug
Lead sponsor
Medicis Global Service Corporation
Industry
Eligibility
18 Years and older · Female only
Enrollment
651 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
37
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Mesa, California + 34 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2013 · Synced Oct 8, 2026, 3:26 AM EDT
Completed Phase 3 Interventional Results available

Study Evaluating the Equivalence of GDC-229 and Metronidazole Vaginal Gel 0.75% in the Treatment of Bacterial Vaginosis

NCT03091777
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
GDC-229, Metronidazole Vaginal Gel 0.75%, Placebo
Drug
Lead sponsor
Balmoral Medical company
Industry
Eligibility
18 Years and older · Female only
Enrollment
871 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 7, 2020 · Synced Oct 8, 2026, 3:26 AM EDT
Completed Phase 3 Interventional Results available

A Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris

NCT03073486
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Olumacostat Glasaretil Gel, 5.0%, Olumacostat Glasaretil Gel, Vehicle
Drug · Other
Lead sponsor
Dermira, Inc.
Industry
Eligibility
9 Years and older
Enrollment
744 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
36
States / cities
Guntersville, Alabama • Glendale, Arizona • Bryant, Arkansas + 32 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2021 · Synced Oct 8, 2026, 3:26 AM EDT
Completed Phase 3 Interventional

Trial of Dapsone 5.0% Gel in the Treatment of Acne Vulgaris

NCT02865005
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Dapsone 5.0% Gel (SEEGPharm), Placebo, Dapsone 5.0% Gel (Allergan)
Drug · Other
Lead sponsor
Seegpharm S.A.
Industry
Eligibility
12 Years to 40 Years
Enrollment
2,361 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
35
States / cities
Encino, California • Fullerton, California • La Mesa, California + 29 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2016 · Synced Oct 8, 2026, 3:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study Evaluating Safety and Tolerability of NVN1000 Gel

NCT01844739
View directory record Official record
Conditions
Acne Vulgaris
Interventions
NVN1000 4% Gel, Vehicle Gel
Drug
Lead sponsor
Novan, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Broomall, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 19, 2018 · Synced Oct 8, 2026, 3:26 AM EDT
Terminated Phase 2 Interventional

Evaluation of the Safety and Efficacy Study of RGN-137 Topical Gel for Junctional and Dystrophic Epidermolysis Bullosa

NCT03578029
View directory record Official record
Conditions
Junctional Epidermolysis Bullosa, Dystrophic Epidermolysis Bullosa
Interventions
RGN-137, Placebo
Drug
Lead sponsor
Lenus Therapeutics, LLC
Industry
Eligibility
4 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
5
States / cities
Evanston, Illinois • Brooklyn, New York • Cincinnati, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2022 · Synced Oct 8, 2026, 3:26 AM EDT